Jeanne G. Vaughn, NP, Kristina Lo, PharmD, BCOP, Jonathan Riess, MD, MS, and Ticiana Leal, MD, discuss the impact of skin toxicities when utilizing EGFR TKIs.
Jeanne G. Vaughn, NP
Advertisement
Articles by Jeanne G. Vaughn, NP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Data Refine the Role of Immunotherapy Across Early-Stage NSCLC Settings
2
Dr Tarantino on the Evolution of TROP2-Directed ADCs in First-Line TNBC
3
Dr Hurvitz on Updated PFS Data From the SERENA-6 Trial in Breast Cancer
4
Ris-Rez Meets Phase 3 Efficacy End Point for R/R Osteosarcoma
5